• Pamela Borgogno, Pehuén Fernández, Walter Douthat, Javier de Arteaga, Juan Carlos Damonte, Virginia Giacomi, Jorge de la Fuente, and Carlos Chiurchiu.
• Servicio de Nefrología, Hospital Privado Universitario de Córdoba, Argentina. E-mail: pameborgogno@hotmail.com.
• Medicina (B Aires). 2021 Jan 1; 81 (6): 986-995.

AbstractThe ABO incompatible (ABOi) living donor (LD) kidney transplant allows increasing the number of donors and reducing the time on the waiting list. The objectives of this study were to compare graft survival, patient survival, rejection risk factors and complications during the first year p ost-transplantation in patients who received an ABOi LD kidney transplant between 2014 and 2019 in our institution, matched according to sex, age and immunological risk with a control group of ABO compatible (ABOc) LD kidney transplants in the same period. Thirteen patients were included in each group. No significant differences were found between ABOi and ABOc in the incidence of delayed graft function (n = 0 vs. 1), bleeding (0 vs. 0), infections (13 vs. 13), cellular rejection (1 vs. 3) and humoral rejection (4 vs. 3) in the first year after transplantation. The rejection rate in ABOi do not seem to be related to blood incompatibility. No risk factors associated with rejection were found. Overall survival of patients was 100% in both groups, and graft survival was 92.3% in ABOi and 100% in ABOc (p = 1). ABOi kidney transplantation is an adequate feasible option in our environment for those who do not have compatible donors.

14 keywords...

hide…